Boehringer Ingelheim Venture Fund related stories
All articles and analysis
Rigontec raises $11.95 mlnRigontec GmbH said Tuesday it raised €9.45 million (US$11.95 million) in a first close of a Series A round co-led by Wellington Partners and Boehringer Ingelheim Venture Fund. Other investors include NRW Bank and High-Tech Gründerfonds. Rigontec, a biopharmaceutical company, is developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.
- Hookipa Biotech raises Series B led by Sofinnova and Forbion Capital
Hookipa Biotech has raised 20 million euros ($27.5 million) in a series B equity financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing with three new investors Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.
- STAT-Diagnostica Appoints Vaillant as Chairman
Medical diagnostics company STAT-Diagnostica has appointed Gérard Vaillant as chairman of the company’s board of directors. Vaillant joins the company following the closing of a Series B financing round totaling $22.1 million, led by Kurma Life Sciences Partners.
- STAT-Diagnostica Raises $22.1 Mln
STAT-Diagnostica closed a Series B round of financing totaling $22.1 million/17 million Euros led by new investor Kurma Life Sciences Partners. Other new investors participating in the round include: Idinvest; Boehringer Ingelheim Venture Fund; and, Caixa Capital Risc, the venture capital division of “la Caixa;” as well as existing investors Ysios Capital and Axis. Barcelona-based STAT-Dianostica develops "near patient testing systems" that aim to simplify and reduce time to results for the diagnosis of certain medical conditions.
- Eyevensys Receives Investment From Boehringer Ingelheim
Eyevensys said it received an equity investment from the Boehringer Ingelheim Venture Fund. Further details were not available. The company raised about $2.1 million in its first round of funding in January 2012. It said early investors - Innobio, managed by CDC Entreprises; Inserm Transfert Initiative; and CapDecisif Management - plan to participate in the second round.
- ArmaGen Technologies Raises $17m Series A
ArmaGen Technologies has closed a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Venture Fund, joined by Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.
- European Fund Briefs, May 2010
Fund-raising news about 3i, 12BF, Boehringer Ingelheim Venture Fund and Emerald Technology Ventures
- Boehringer Ingelheim Launches Corporate VC Fund
Boehringer Ingelheim, a German pharmaceutical company, has launched a €100 million corporate venture fund. The vehicle will invest in startups "that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science. "